toreforant

an orally active histamine H4-receptor antagonist

Also Known As:

2-pyrimidinamine, 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-(3-(1-methyl-4-piperidinyl)propyl)-; 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-(3-(1-methyl-4-piperidinyl)propyl)-2-pyrimidinamine

Networked: 5 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - toreforant: 5
  - Piperidines: 17
    - toreforant: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - toreforant: 5

Experts

1.	Thurmond, Robin L: 5 articles (04/2019 - 01/2016)
2.	Dunford, Paul J: 2 articles (04/2019 - 01/2017)
3.	Chen, Bin: 2 articles (11/2018 - 01/2016)
4.	Zhou, Bei: 2 articles (11/2018 - 01/2016)
5.	Barchuk, William: 1 article (04/2019)
6.	Boyle, David L: 1 article (04/2019)
7.	Calderon, Cesar: 1 article (04/2019)
8.	Chen, Dion: 1 article (04/2019)
9.	DePrimo, Samuel E: 1 article (04/2019)
10.	Firestein, Gary S: 1 article (04/2019)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/01/2018 - "Toreforant, at the dose tested, failed to provide therapeutic benefit in this population of patients with uncontrolled, eosinophilic, persistent asthma. " 11/01/2018 - "To evaluate the efficacy and safety of toreforant in patients with eosinophilic, persistent asthma that was inadequately controlled despite current treatment. " 11/01/2018 - "Toreforant is a selective histamine 4 receptor antagonist that could be effective in patients with eosinophilic asthma. " 11/01/2018 - "A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma." 01/01/2017 - "Toreforant has been tested in clinical studies in patients with rheumatoid arthritis, asthma, or psoriasis. "
2.	Rheumatoid Arthritis 04/01/2019 - "Patients with active rheumatoid arthritis (RA) despite methotrexate were randomized (3:1) to toreforant 30 mg/day (weeks 0-52) or placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52). " 01/01/2016 - "To assess toreforant (selective histamine H4 receptor antagonist) in active rheumatoid arthritis (RA). " 01/01/2017 - "Toreforant has been tested in clinical studies in patients with rheumatoid arthritis, asthma, or psoriasis. " 04/01/2019 - "Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study." 01/01/2016 - "Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 08/01/2018 - "To evaluate Toreforant efficacy and safety in patients with moderate-to-severe psoriasis. " 08/01/2018 - "Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial." 01/01/2017 - "Toreforant has been tested in clinical studies in patients with rheumatoid arthritis, asthma, or psoriasis. "

Related Drugs and Biologics

1.	Histamine (Histamine Dihydrochloride)
2.	Histamine H4 Receptors
3.	Methotrexate (Mexate)

Related Therapies and Procedures

1.	Therapeutics